Literature DB >> 23391464

A major event for new tuberculosis vaccines.

Christopher Dye1, Paul E M Fine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23391464     DOI： 10.1016/S0140-6736(13)60137-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

1.  Control of Mycobacterial Infections in Mice Expressing Human Tumor Necrosis Factor (TNF) but Not Mouse TNF.

Authors:  Maria L Olleros; Leslie Chavez-Galan; Noria Segueni; Marie L Bourigault; Dominique Vesin; Andrey A Kruglov; Marina S Drutskaya; Ruth Bisig; Stefan Ehlers; Sahar Aly; Kerstin Walter; Dmitry V Kuprash; Miliana Chouchkova; Sergei V Kozlov; François Erard; Bernard Ryffel; Valérie F J Quesniaux; Sergei A Nedospasov; Irene Garcia
Journal:  Infect Immun       Date:  2015-06-29       Impact factor: 3.441

2.  Multicenter Evaluation of Anyplex Plus MTB/NTM MDR-TB Assay for Rapid Detection of Mycobacterium tuberculosis Complex and Multidrug-Resistant Isolates in Pulmonary and Extrapulmonary Specimens.

Authors:  Michela Sali; Flavio De Maio; Francesca Caccuri; Federica Campilongo; Maurizio Sanguinetti; Simona Fiorentini; Giovanni Delogu; Cinzia Giagulli
Journal:  J Clin Microbiol       Date:  2015-10-21       Impact factor: 5.948

3.  Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.

Authors:  Marco Schito; Giovanni Battista Migliori; Helen A Fletcher; Ruth McNerney; Rosella Centis; Lia D'Ambrosio; Matthew Bates; Gibson Kibiki; Nathan Kapata; Tumena Corrah; Jamshed Bomanji; Cris Vilaplana; Daniel Johnson; Peter Mwaba; Markus Maeurer; Alimuddin Zumla
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079

Review 4.  Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.

Authors:  Yuan-qiang Zheng; Youssef W Naguib; Yixuan Dong; Yan-chun Shi; Shorgan Bou; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2015       Impact factor: 5.217

5.  Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.

Authors:  Gwenan M Knight; Ulla K Griffiths; Tom Sumner; Yoko V Laurence; Adrian Gheorghe; Anna Vassall; Philippe Glaziou; Richard G White
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-06       Impact factor: 11.205

6.  Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered.

Authors:  Christopher Dye
Journal:  J R Soc Interface       Date:  2013-07-31       Impact factor: 4.118

7.  Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.

Authors:  Tandakha N Dieye; Birahim P Ndiaye; Alle B Dieng; Marema Fall; Nathaniel Brittain; Nathaniel Britain; Samantha Vermaak; Makhtar Camara; Halimatou Diop-Ndiaye; Ndeye Fatou Ngom-Gueye; Papa A Diaw; Coumba Toure-Kane; Papa S Sow; Souleymane Mboup; Helen McShane
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

8.  Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A.

Authors:  Magali Matsumiya; Elena Stylianou; Kristin Griffiths; Zoe Lang; Joel Meyer; Stephanie A Harris; Rosalind Rowland; Angela M Minassian; Ansar A Pathan; Helen Fletcher; Helen McShane
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

Review 9.  Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations.

Authors:  Amaya Leunda; Aline Baldo; Martine Goossens; Kris Huygen; Philippe Herman; Marta Romano
Journal:  Vaccines (Basel)       Date:  2014-06-16

10.  The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.

Authors:  Michele Tameris; Hennie Geldenhuys; Angelique KanyKany Luabeya; Erica Smit; Jane E Hughes; Samantha Vermaak; Willem A Hanekom; Mark Hatherill; Hassan Mahomed; Helen McShane; Thomas J Scriba
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.